High-dose chemotherapy for breast cancer: The French PEGASE experience

Cancer Control

Volumn 10, Issue 1, 2003, Pages 42-47

  Roché, Henri ^a   Viens, Patrice ^b   Biron, Pierre ^c   Lotz, Jean Pierre ^d   Asselain, Bernard ^e  

^a INSTITUT CLAUDIUS REGAUD   (France)

^b INSTITUT PAOLI CALMETTES   (France)

^c CENTRE LÉON BÉRARD   (France)

^d HÔPITAL TENON   (France)

^e INSTITUT CURIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; MITOXANTRONE; TAMOXIFEN; THIOTEPA;

ADVANCED CANCER; ARTICLE; BONE MARROW TRANSPLANTATION; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DOSE RESPONSE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LYMPH NODE METASTASIS; MASTECTOMY; MENOPAUSE; METASTASIS; NEUTROPENIA; OUTCOMES RESEARCH; PATIENT SELECTION; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; VEIN OCCLUSION;

EID: 0037286183     PISSN: 10732748     EISSN: None     Source Type: Journal    
DOI: 10.1177/107327480301000105     Document Type: Article

References (14)

1. Antman KH, Souhami RL. High-dose chemotherapy in solid tumours: a review of published data in selected tumours with a commentary. Ann Oncol. 1993;4(suppl 1):29-44.
2. Peters WP Ross M, Vredenburgh JJ, et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol. 1993;11:1132-1143.
3. Coiffier B, Philip T, Burnett A, et al. consensus conference on intensive chemotherapy plus hematopoietic stem cell transplantation in malignancies, Lyon, June 4-6, 1993. Ann Oncol. 1994;5:19-23.
4. Roché HH, Pierre Pouillart P, Meyer N, et al. Adjuvant high dose chemotherapy (HDC) improves early outcome for high risk (n>7) breast cancer patients: the Pegase 01 trial. Proc Annu Meet Am Soc Clin Oncol. 2001. Abstract 102.
5. Rodenhuis S, Bontenbal M, Beex LVAM, et al. Randomized phase III study of high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin in operable breast cancer with 4 or more axillary lymph nodes. Proc Annu Meet Am Soc Clin Oncol. 2000. Abstract 286.
6. Bergh J, Wiklund T, Erikstein B, et al. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study. Lancet. 2000;356:1384-1391.
7. Viens P, Palangié T, Janvier M, et al. High pathologic complete response rate of inflammatory breast cancer to high dose sequential cyclophosphamide-doxorubicin-5FU with rh-G-CSF and repeated blood stem cell support: In: Program and abstracts of the 21st Annual San Antonio Breast Cancer Symposium; December 12, 1998; San Antonio,Texas. Abstract 146.
8. Viens P, Palangié T, Janvier M, et al. First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial). Br J Cancer. 1999;81:449-456.
9. Macquart-Moulin G, Viens P, Palangié T, et al. High-dose sequential chemotherapy with recombinant granulocyte colony-stimulating factor and repeated stem-cell support for inflammatory breast cancer patients: does impact on quality of life jeopardize feasibility and acceptability of treatment? J Clin Oncol. 2000;18:754-764.
10. Palangié T, Roché H, Viens P, et al. Taxotere (TXT) in sequential association with multiple cycles high dose doxorubicin (D) and cyclophosphamide (C) as first line therapy in Inflammatory Breast Cancer French Collaborative FNCLCC Study. Proc Annu Meet Am Soc Clin Oncol. 2000. Abstract 227.
11. Biron P, Durand M, Roché H, et al. High dose thiotepa (TTP), cyclophosphamide (CPM) and stem cell transplantation after 4 FEC 100 compared with 4 FEC alone allowed a better disease free survival but the same overall survival in first line chemotherapy for metastatic breast cancer: results of the PEGASE 03 French Protocole. Proc Annu MeetAm Soc Clin Oncol. 2002. Abstract 167.
12. Lotz J, Cure H,Janvier M, et al. High-dose chemotherapy (HD-CT) with hematopoietic stem cell transplantation (HSCT) for metastatic breast cancer (MBC): results of the French Protocol PEGASE 04. Proc Annu Meet Am Soc Clin Oncol. 1999. Abstract.
13. Crump M, Gluck S,Stewart D, et al. A randomized trial of high-dose chemotherapy (HDC) with autologous peripheral blood stem cell support (ASCT) compared to standard therapy in women with metastatic breast cancer: a National Cancer Institute of Canada (NCIC) Clinical Trials Group study. Proc Annu Meet Am Soc Clin Oncol. 2001. Abstract 82.
14. Crown JP, Lind M, Gould A, et al. High-dose chemotherapy (HDC) with autograft (PBP) support is not superior to cyclophosphamide (CPA), methotrexate and 5-FU (CMF) following doxorubicin (D) inductin in patients (pts) with breast cancer (BC) and 4 or more involved axillary lymph nodes (4+LN): the Anglo-Celtic I study. Proc Annu Meet Am Soc Clin Oncol. 2002. Abstract 166.